Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
The concerns about the development of adverse events (AEs) in elderly RA patients as a result of age-related changes in drug metabolism and the presence of comorbid illnesses are emphasizing due to increasing prevalence of rheumatoid arthritis (RA) in old age.